The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Eur Urol. 2018 Apr;73(4):485-487. doi: 10.1016/j.eururo.2017.10.027. Epub 2017 Nov 11.
The use of [F]- and [Ga]-labeled inhibitors of prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of prostate cancer is now widespread. We have proposed a reporting and data system called PSMA-RADS version 1.0, which is a framework for classifying PSMA-targeted PET scans and individual findings into categories that reflect the likelihood of the presence of prostate cancer.
目前，使用 [F]-和 [Ga]-标记的前列腺特异性膜抗原（PSMA）抑制剂进行正电子发射断层扫描（PET）成像来诊断前列腺癌已经较为广泛。我们提出了一种称为 PSMA-RADS 版本 1.0 的报告和数据系统，该系统是一种将 PSMA 靶向 PET 扫描和各个发现分类为反映前列腺癌存在可能性的类别框架。
